MD Anderson Cancer Center

Site:	MD Anderson Cancer Center	Go to their website
Address:	1505 Holcombe Blvd.
City:	Houston
State:	TX
Zip:	77030
Country:	USA

62 trials at this site

Phase	Trial	Trial Status [asc]	Site Status	Drug	NCT#
1	Administration of BIIB028 to Subjects With Solid Tumors	Ongoing, but not recruiting	Closed	BIIB028	NCT00725933
1	A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer	Ongoing, but not recruiting	Closed	BEZ235	NCT00620594
1	Phase I Study of Pazopanib and Vorinostat	Ongoing, but not recruiting	Closed	Pazopanib (Votrient) + vorinostat (Zolinza)	NCT01339871
1	Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients	Ongoing, but not recruiting	Closed	BEZ235 + MEK162	NCT01337765
1	A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients	Ongoing, but not recruiting	Closed	BKM120 + GSK1120212	NCT01155453
1	Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer	Ongoing, but not recruiting	Closed	Pazopanib + Trametinib	NCT01438554
1	Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer	Ongoing, but not recruiting	Closed	BAY80-6946 + BAY86-9766	NCT01392521
	Symptom Inventory for Gastrointestinal Stromal Tumors	Ongoing, but not recruiting	Closed		NCT01178307
1/2	Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion	Recruiting	Active	MRTX1719	NCT05245500
3	A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)	Recruiting	Active	Ripretinib	NCT05734105
2	Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)	Recruiting	Active	Belzutifan	NCT04924075
2	Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.	Recruiting	Active	Regorafenib	NCT06087263
1	A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1]	Recruiting	Active	IDRX-42	NCT05489237
1	A Study of NB003 in Patients With Advanced Malignancies	Recruiting	Active	NB003	NCT04936178
1	A Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced And/or Metastatic Solid Tumors Known to Express C-Kit	Recruiting	Active	NN3201	NCT06805825
1	A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)	Recruiting	Active	Ziftomenib + Imatinib	NCT06655246
1/2	Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors	Terminated	Closed	CB-839 + Talazoparib	NCT03875313
3	Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients	Terminated	Closed	Imatinib	NCT01031628
2	Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery	Terminated	Closed	Imatinib + Oblimersen	NCT00091078
1	A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors	Terminated	Closed	Trametinib + Palbociclib	NCT02065063

MD Anderson Cancer Center

62 trials at this site

First | Previous | Page 3 of 4 | Next | Last